News & Press Releases

UroViu Corporation announced today that it has received CE certification for its cystoscopic  product portfolio. This includes the reusable UV4500 Handle and the disposable Hystero-V, Uro-V, and Uro-GHD endoscopes. “This CE certification marks an important milestone for UroViu and for patients worldwide,” said Bruce OuYang, Ph.D., CEO. “It enables us to bring the most versatile, portable and environmentally friendly portfolio of cystoscopes to patients in any region that accepts the CE Marking.” This certification also lays a foundation for fast-track approval of future new releases or upgrades within the same product line. The UroViu portfolio has been widely adopted across various segments of the U.S. Urology and UroGynecology market, including private practices, Ambulatory Surgical Centers (ASCs), academic institutions, VA, and DOD healthcare facilities. UroViu  products offer several unique features: Self Contained, Cordless, Untethered Design: This design minimizes environmental impact and the carbon footprint of disposable products by eliminating the need

UroViu Receives FDA 510(k) Clearance for Its UV5000W Wi-Fi Enabled Advanced Endoscope Platform UroViu Corporation is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its UV5000W Wi-Fi-enabled cordless, single-use endoscope platform. The UV5000W combines the recently cleared UV5000 with a Wi-Fi relay, allowing connection to any external display. As Bruce OuYang, Ph.D., CEO of UroViu, commented, “The UV5000W setup now allows the clinician the option to keep his/her eyesight in the axis of operations, while the simultaneous external display allows visualization by the patients and other clinicians as needed. Clearance of the UV5000W Wi-Fi platform is a major advance in endoscopy that allows secure wireless connectivity within a busy and crowded procedure room.” UroViu is committed to its goal to “Simplify the Scope of Patient Care” and revolutionizing embedded single-use visualization. The UV5000W is immediately available in the U.S. market. For more

UroViu Corporation is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its UV5000 cordless, single-use endoscope platform. The UV5000 replaces the current UV4500 on the market, offering a faster processor, longer battery life, and brighter HD visualization directly within the clinician’s line of sight. It is compatible with all of UroViu’s single-use endoscope cannulas, graspers, and biopsy forceps.  As a companion to the UV5000, UroViu has submitted a 510(k) application for a model, the UV5000W, that has built-in Wi-Fi connectivity to external displays. Bruce OuYang, Ph.D., CEO, commented, “UroViu strives to achieve a win-win situation for patients and care providers and has gained adoption across all segments of the market, including private practices, ASCs, academic institutions, VA, and DOD healthcare facilities, benefiting from the following unique features: Cordless, untethered design: This minimizes the environmental impact and carbon footprint of disposable products by

Asieris Pharmaceuticals, a global biopharmaceutical company dedicated to pioneering innovative treatments for genitourinary tumors and related diseases, has recently announced an exciting development in its partnership with UroViu Corporation (“UroViu”). This strategic collaboration grants Asieris exclusive global rights to utilize UroViu’s patented portable single-use cystoscope technology in the domain of fluorescent imaging. This advancement marks a significant step forward in the quest to enhance the diagnosis and postoperative monitoring of Non-Muscle Invasive Bladder Cancer (NMBC) through cutting-edge non-white light imaging techniques. Asieris Pharmaceuticals will not only spearhead the research efforts in this area but will also take charge of the worldwide commercialization of the sterile single-use fluorescent Cystoscope. Read the Full Press Release Here

UroViu Corp has introduced the brand-new Uro-GHD, a sterile, disposable cystoscope that seamlessly integrates with UroViu’s innovative Always Ready endoscopy system. Notably, the Uro-GHD boasts a cutting-edge 1280×720 pixel sensor, marking a groundbreaking advancement in the realm of portable, disposable endoscopy tools. Furthermore, this novel cystoscope incorporates an enhanced, pliable cannula with a tapered tip, prioritizing patient comfort. According to Dr. Joseph Liao from Stanford University School of Medicine, the substantial enhancement in image quality achieved with the UroViu GHD positions it at the forefront of digital cystoscope technology for bladder cancer surveillance. A recent survey of users underscores the newfound maneuverability coupled with superior optics and an updated HD sensor, enabling healthcare professionals to effortlessly and effectively carry out procedures such as bladder cancer surveillance and stent removals. UroViu’s Always Ready endoscopy system comprises a reusable, self-contained, highly portable handle and a suite of four purpose-designed, single-use cystoscopes. Read

UroViu Corp, a firm specializing in the creation and distribution of exceptionally portable single-use endoscopy solutions, has proudly announced its inclusion in the US Defense Logistics Agency’s Medical Equipment ECAT. Through a secured contract facilitated by Fidelis Sustainability Distribution, veterans will now gain access to cutting-edge cystoscopy equipment. As per the terms of the agreement, UroViu will offer its entire range of products at a predetermined price, exclusively for distribution by Fidelis. These products will be made accessible to over 1,200 VA and DOD healthcare facilities across the United States, collectively serving a remarkable 9 million enrolled veterans annually. Read the Full Press Release